Sequoia-backed Indian anti-virus software firm files for IPO: Reuters

Indian anti-virus software maker Quick Heal Technologies Ltd, which is backed by Sequoia Capital, filed a prospectus for a stock listing with the domestic market regulator on Wednesday. The IPO will involve the sale of new shares worth up to 2.5 billion rupees ($38.03 million) and 6.8 million shares currently held by promoters including Indian units of Sequoia Capital and company founders, Quick Heal said in a statement. Sequoia, which currently holds more than 10 percent stake in Quick Heal, is looking to sell about 4.6 percent of its stake, according to a source familiar with the matter. ICICI Securities, Jefferies and JP Morgan will be the underwriters, according to Quick Heal.

Go here to read the rest:
Sequoia-backed Indian anti-virus software firm files for IPO: Reuters

Monroe Capital provides loan for Hammond, Kennedy’s buy of Partners in Leadership

Monroe Capital LLC said Tuesday that it provided a loan to support Hammond, Kennedy, Whitney & Company Inc.’s buy of Partners in Leadership Inc. Financial terms weren’t announced. Temecula, California-based Partners in Leadership provides accountability and cultural transition training services to companies. PRESS RELEASE September 29, 2015 06:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Monroe Capital LLC today announced it acted as sole lead arranger and administrative agent on the funding of a unitranche credit facility to support the acquisition of Partners in Leadership, Inc. (“PIL”) by private equity sponsor, Hammond, Kennedy, Whitney & Company, Inc. Based in Temecula, California, PIL is a leading provider of accountability and cultural transition training services to blue-chip companies in more than 42 countries. The company’s training ties accountability for key organizational results directly to individual work objectives and enables organizations to define and create needed shifts in the way their people go about achieving results and creating a culture of accountability. About Monroe Capital Monroe Capital LLC is a leading provider of senior and junior debt and equity co-investments to middle-market companies in the U.S. and Canada. Investment types include unitranche financings, cash flow and enterprise value based loans, acquisition facilities, mezzanine debt, second lien or last-out loans and equity co-investments. Monroe Capital prides itself on its flexible investment approach and its ability to close and fund transactions quickly. Monroe is committed to being a value-added and user-friendly partner to owners, senior management and private equity sponsors. Monroe has been recognized by Global M&A Network as the 2013 and 2014 Small Mid-Market Lender of the Year, Private Debt Investor as the 2013 Unitranche Lender of the Year and 2014 Senior Lender of the Year, and the U.S. Small Business Administration as the 2015 Small Business Investment Company (SBIC) of the Year. To learn more about Monroe Capital LLC, visit www.monroecap.com.

Read more:
Monroe Capital provides loan for Hammond, Kennedy’s buy of Partners in Leadership

Apax invests in Ideal Protein

Apax Partners LLP said Friday it has agreed to invest in Ideal Protein. Financial terms weren’t announced. The founders, Dr. Tran Tien Chanh and Olivier Benloulou, will continue to have a significant stake. Ideal Protein, of Gatineau, Quebec, is a weight loss and wellness solutions company. Jefferies LLC advised Ideal Protein while BMO Capital Markets acted as financial advisor to Apax. PRESS RELEASE NEW YORK and GATINEAU, Quebec, Sept. 25, 2015 /PRNewswire/ — Funds advised by Apax Partners LLP (“Apax”), a global private equity firm, today announced that they have entered into a definitive agreement to acquire an interest in Ideal Protein, a proprietary weight loss and wellness solutions company. Terms of the transaction were not disclosed. Ideal Protein has developed a comprehensive protocol that is intended to help individuals successfully achieve and maintain their weight-loss goals. The company has partnered with over 3,000 physician offices, medical clinics, multi-provider practices, chiropractors and pharmacies in the U.S. and Canada who offer and administer the program to dieters. Patients follow a nutritional ketogenic weight loss protocol and receive education and coaching through trained clinic partners. The company was founded in 2004 by Dr. Tran Tien Chanh, a doctor of medicine and nutritional expert, and Olivier Benloulou, an entrepreneur in the food and natural health industries. The founders will continue to have a significant ownership interest in the company following the closing of the transaction. Buddy Gumina, Partner and Co-Head of Healthcare at Apax Partners, said, “Olivier Benloulou and Dr. Tran Tien Chanh have created an industry-leading platform in the weight-management space. Ideal Protein’s unique clinic-partner model has rapidly expanded in the U.S. and Canada, and we look forward to working with the founders and management team to build upon its success and further accelerate growth globally.” “We are thrilled to partner with the Apax Partners team and leverage their vast expertise in healthcare and other sectors,” said Olivier Benloulou, President and CEO of Ideal Protein. “As we continue to expand our clinic partnerships, enter new markets and work to help more individuals achieve their weight-loss goals, Apax’s resources and deep knowledge of healthcare services will be instrumental.” “We founded Ideal Protein with the vision to revolutionize the approach to helping the over 150 million adults who are overweight in today’s market,” said Dr. Tran Tien Chanh, co-founder of Ideal Protein. “Many people have achieved success using our weight loss protocol and we look forward to working with Apax to further enhance our services, brand recognition and market presence to take our business to the next level.” Apax is one of the leading global investors in the healthcare sector, having completed more than 100 investments over the last 30 years across multiple geographies in North America, Europe and Asia. The Apax Healthcare team has deep sector expertise in key fields including healthcare services, devices and products, pharmaceuticals and healthcare IT. Current and past healthcare investments include Acelity, One Call Care Management, Genex and TriZetto Corporation in the U.S.; Capio, Unilabs and Mölnlycke in Europe; and Apollo Hospitals in India. The transaction is subject to customary closing conditions and is expected to close in the coming weeks. Ideal Protein and its Shareholders were advised by Jefferies LLC and PricewaterhouseCoopers Corporate Finance LLC and were represented by McCarthy Tétrault LLP in Canada and by Duane Morris LLP in the United States. Kirkland & Ellis LLP, Epstein Becker & Green P.C. and Blake, Cassels & Graydon LLP represented Apax Partners. BMO Capital Markets acted as financial advisor to Apax. About Ideal Protein Ideal Protein is a proprietary, ketogenic weight loss program that was developed over 20 years ago by physician Dr. Tran Tien Chanh. Ideal Protein’s protocol is based on validated science that is designed for weight loss. Ideal Protein’s program helps maintain vitality while triggering ketosis, a mechanism by which the body burns fat efficiently. This data-driven protocol coupled with turnkey coaching is designed to move dieters toward an ideal weight as well as help them support and maintain their weight. Ideal Protein is now available in thousands of physician, cardiologist and health care practitioners’ offices, pharmacies and weight loss clinics in North America. Ideal Protein also has manufacturing operations in Quebec City, all of which will be included in this transaction. For more information visit our website www.idealprotein.com. About Apax Partners LLP Apax Partners is a leading global private equity advisory firm. It operates globally and has more than 30 years of investing experience. Apax Partners has advised funds that total over €34 billion in aggregate as at 31 March 2015. Funds advised by Apax invest in companies across four global sectors of Healthcare, Consumer, Tech & Telco and Services. These funds provide longterm equity financing to build and strengthen world-class companies. For further information about Apax, please visit www.apax.com. Apax Partners LLP is authorised and regulated by the FCA in the UK and is subject to the FCA’s rules and guidance. Apax Partners’ registered office is 33 Jermyn Street, London, SW1Y 6DN, UK.

See the rest here:
Apax invests in Ideal Protein

Auris Surgical Robotics snags $150 mln

Auris Surgical Robotics, a developer of robotics technology, has raised $150 million in funding, according to an SEC filing. Last year, Auris secured $34.4 million in Series A funding from Highland Capital Partners, Lux Capital, Mithril Capital Management and NaviMed Capital, reported Crunchbase.

More here:
Auris Surgical Robotics snags $150 mln

Riverside exits Orliman

Magnum Capital has acquired Riverside Company‘s ownership stake in Orliman. No financial terms were disclosed. Montalban and KPMG served as advisors to Riverside on the transaction. Based in Valencia, Spain, Orliman is a maker of orthopedic devices. PRESS RELEASE (PRWEB) SEPTEMBER 24, 2015 The Riverside Company has sold its ownership stake in Orliman to Iberian Private Equity firm Magnum Capital. Orliman is a Spanish manufacturer and distributor of non-invasive orthopedic devices. The company’s products are used in the prevention of injury, treatment of chronic conditions and for recovery after surgery or injury. Based in Valencia Spain, Orliman manufactures a broad portfolio of devices for the upper limb, torso and lower limb including both standard as well as made-to-measure products. After investing in Orliman in 2010, Riverside expanded the company considerably through both organic growth and integration of add-on acquisition. These efforts helped to extend Orliman’s leadership position in its market and accelerated the company’s transformation into the leading player within Southern Europe. During Riverside’s hold period, Orliman’s sales by more than 50% and EBITDA nearly doubled. Among other improvements, Riverside incorporated new senior leadership, further invested in new product development, and reinforced the export department by increasing the company’s presence in selected markets throughout the world. In 2014, Riverside completed the acquisition of French orthopedic company Soft Medical Europe. Today, Orliman sells in more than 40 countries and 70% of sales are generated outside of Spain. “We’re very proud of the work we did at Orliman,” said Riverside Principal Rafael Álvarez-Novoa. “It went from a family-owned business to a growing international enterprise during our hold. Orliman has proven to be a very solid and stable business, with strong leadership position in its core markets and very promising exports business that grows above 15% every year.” Working with Álvarez-Novoa on the transaction for Riverside were Vice President Damien Gaudin and Operating Executive Juan Rufilanchas. Montalban and KPMG advised Riverside on the transaction, and Garrigues acted as legal counsel for the firm. The Riverside Company (http://www.riversidecompany.com or http://www.riversideeurope.com) The Riverside Company is a global private equity firm focused on investing in and acquiring growing businesses valued at up to $300 million. Since its founding in 1988, Riverside has invested in more than 400 transactions. The firm’s international portfolio includes more than 80 companies.

Read more here:
Riverside exits Orliman